‘Most Favored Nation’ Drug Pricing Is An Idea Whose Time Has Come Author: James C. Robinson

https://www.healthaffairs.org/doi/10.1377/hlthaff.2025.01127?utm_campaign=april+2026+issue&utm_medium=email&_hsenc=p2ANqtz--lSJogOFQls3_NOS73argN08A8JSV0-2LIb6sTLl3aLchuJHspaSkM4k810vmsd-gYKNywdi_My1A7UZmrnMs8vcRRrw&_hsmi=416613978&utm_source=well+read This commentary evaluates the policy instruments available to address high US drug prices and considers how most‑favored‑nation pricing may influence global pricing dynamics and pharmaceutical innovation.